Gender-affirming hormone therapy was not associated with increased rates of type 2 diabetes among transgender people, according to a study in the Journal of Clinical Endocrinology & Metabolism. The findings were based on data for 5,002 transgender individuals and matched control groups totaling about 96,000 cisgender individuals.
Full Story: Contemporary OB/GYN (12/10)